Jefferson Davis
Psychiatry · Santa Fe, NMNPI 1669523502
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $43,957 of the $53,095 with a category attached, or 82.8%. 18 manufacturers reported payments, led by AbbVie at 45.2% of the total. Reporting peaked in 2022 at $20,907 and has fallen 99.9% since, to $27 in 2025. Among psychiatry clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 392 payments — averaging $135.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$24K
- Teva Pharmaceuticals USA, Inc.$18K
- Sunovion Pharmaceuticals Inc.$6K
- Otsuka America Pharmaceutical, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$841
- Takeda Pharmaceuticals U.S.A., Inc.$709
- plus $2K from 12 others
What the payments were for
- Consulting fees$2000%
- Speaking & faculty fees$43,95783%
- Travel & lodging$1,3653%
- Food & beverage$7,43114%
- Education$1420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 65 | $24,019 |
| Teva Pharmaceuticals USA, Inc. | 41 | $18,401 |
| Sunovion Pharmaceuticals Inc. | 57 | $6,244 |
| Otsuka America Pharmaceutical, Inc. | 55 | $1,031 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 38 | $841 |
| Takeda Pharmaceuticals U.S.A., Inc. | 43 | $709 |
| Merck | 27 | $439 |
| Lundbeck LLC | 16 | $323 |
| Johnson & Johnson | 14 | $264 |
| Janssen Scientific Affairs, LLC | 1 | $200 |
| Axsome Therapeutics, Inc. | 6 | $128 |
| Eisai Inc. | 6 | $106 |
| Jazz Pharmaceuticals Inc. | 6 | $95 |
| Alkermes, Inc. | 4 | $74 |
| Biodelivery Sciences International, Inc. | 4 | $65 |
| Supernus Pharmaceuticals, Inc. | 4 | $62 |
| Neurocrine Biosciences, Inc. | 3 | $55 |
| Corium, LLC | 2 | $39 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$53,095 in reported general payments places this provider in the 95th percentile of 174 psychiatry providers in New Mexico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 21 | $1,839 |
| Lurasidone Hcl | 11 | $1,572 |
| Duloxetine Hcl | 30 | $739 |
| Bupropion XlBupropion Hcl | 27 | $681 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 23 | $566 |
| Escitalopram Oxalate | 26 | $559 |
| Quetiapine Fumarate | 15 | $496 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $424 |
| Methylphenidate Hcl | 14 | $398 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 14 | $368 |
| Gabapentin | 13 | $366 |
| Sertraline Hcl | 11 | $358 |
| Trazodone Hcl | 25 | $343 |
| Fluoxetine Hcl | 13 | $338 |
| Lamotrigine | 21 | $272 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Santa Fe
- Daniel CollinsSanta Fe$2K
- Barry AltenbergSanta Fe$478
- Edward NeidhardtSanta Fe$394
- Mary RoesselSanta Fe$394
- Jafet Gonzalez ZakarchencoSanta Fe$353
- Douglas PuryearSanta Fe$218
- Patricio EscalonaAlbuquerque$487K
- Mauricio TohenAlbuquerque$160K
- Shiva SharmaAlbuquerque$140K
- Ernest FloresLas Cruces$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.